DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/j4xgjw/next_generation) has announced the addition of the Global NGS Market 2013 Report to their offering.

The report reviews the market size, segmentation, growth and trends of the Next generation sequencing (and third generation sequencing) market.

The NGS is assessed across five segments:

Company

Product type

• Instrument
• Reagents
• Services

Customer

• Academia
• Biopharma
• Applied Markets
• Clinical
• Other

Instrument type

Geography

• US
• Europe
• Japan
• Asia/Pacific
• Others

For each of these segments, an annual market size and growth from 2009 to 2015 is provided, as well as key growth drivers and moderators.

Hot topics covered include the emerging adoption of NGS in clinical settings and the continued decentralization driven by desktop sequencers (e.g., Ion Proton, MiSeq).

Market Highlights

NGS is the fastest growing and the most attractive segment of the $7.1B genomics space (manufacturer market). With an estimated market size of -$1.2B in 2012, and a double digit growth rate, this market is expected to reach $2.1B in 2015, driven by adoption in non-academic customers, especially clinical customers. NGS is poised to revolutionize not only medical research in academic laboratories and Biopharma, but also the healthcare landscape and applied markets (e.g., AgBio, food testing).

Growth Factors

1) increased reagent usage on an expanding instrument installed base

2) continued decentralization via desktop sequencers such as Illumina's MiSeq that make the technology accessible to individual academic laboratories and in clinical settings

3) increased adoption of the technology by new customers (e.g., Applied markets such as AgBio, patients in clinical trials)

4) increased usage for new scientific applications beyond pure sequencing (e.g., expression profiling, ChIP-Seq, methylation studies)

5) broader adoption of sequencing services (e.g., BGI/Complete Genomics).

Risks

1) increasing pricing pressure driven by more affordable instrument options and continued technological improvements leading to cheaper cost per base pair and technology commoditization

2) increasing use of service providers offering an alternative to in-house platform adoption, as many customers don't have the budget for / interest in large capital expenditures for such fast-evolving technologies

3) continuing workflow and bioinformatics issues, especially for more translational applications

4) continuing unfavorable research funding dynamics in the U.S. - especially in light of budget sequestration - and abroad.

Companies Mentioned

• Illumina
• Life Technologies / Ion Torrent
• Roche / 454 Life Sciences
• Pacific Biosciences
• BGI / Complete Genomics

For more information visit http://www.researchandmarkets.com/research/j4xgjw/next_generation

About Research and Markets

Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.